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ABSTRACT
The multifunctional human DNA2 (hDNA2)
nuclease/helicase is required to process DNA
ends for homology-directed recombination repair
(HDR) and to counteract replication stress. To partic-
ipate in these processes, hDNA2 must localize to the
nucleus and be recruited to the replication or repair
sites. However, because hDNA2 lacks the nuclear
localization signal that is found in its yeast homolog,
it is unclear how its migration into the nucleus is
regulated during replication or in response to DNA
damage. Here, we report that the E3 ligase TRAF6
binds to and mediates the K63-linked polyubiquitina-
tion of hDNA2, increasing the stability of hDNA2 and
promoting its nuclear localization. Inhibiting TRAF6-
mediated polyubiquitination abolishes the nuclear
localization of hDNA2, consequently impairing DNA
end resection and HDR. Thus, the current study
reveals a mechanism for the regulation of hDNA2
localization and establishes that TRAF6-mediated
hDNA2 ubiquitination activates DNA repair pathways
to maintain nuclear genome integrity.
INTRODUCTION
DNA replication is the central process that ensures the
faithful transmission of genetic information from parental
cells to daughter cells (1,2). However, this process is fre-
quently perturbed by endogenous factors and environ-
mental agents that cause DNA damage (3–5). Replication
stresses cause DNA replication forks to stall and collapse
if not stabilized and repaired, resulting in mutations and
chromosomal rearrangements, which are hallmarks of pre-
cancerous cells (5–10). Therefore, the ability of cells to re-
spond to DNA replication stresses is essential to maintain
genomic integrity. Genetic and molecular studies indicate
that the highly conserved DNA2 nuclease/helicase plays
a crucial role in counteracting replication stresses (11–13).
Originally identified for its role in Okazaki fragment mat-
uration during nuclear DNA replication in yeast cells (14–
20), DNA2 is now recognized as a multifunctional nucle-
ase that is also required for double-strand break (DSB) re-
pair (21–24) and maintaining telomere stability (25–28) in
both yeast and mammalian cells. It has also been shown
that yeast DNA2 (yDNA2) binds to and maintains the
stability of the replication fork to prevent it from revers-
ing and collapsing (29). yDNA2 nuclease deficiency re-
sults in large and complex DNA insertions at chromo-
somal breaks (30). Recently, we demonstrated that hu-
man DNA2 (hDNA2) localizes to the centromere region
(31), which contains predominantly secondary structure-
forming -satellite repetitive DNA sequence (32,33). We
further revealed that hDNA2 is essential for efficient repli-
cation of this region (31).
Although hDNA2and othermammalianDNA2proteins
have enzymatic activities similar to that of yDNA2 (34–36),
they lack the classic nuclear localization signal (NLS) found
in yDNA2 and predominantly localize to the mitochondria
under normal culture conditions (36). However, maintain-
ing the integrity of telomeres and centromeres and process-
ing stalled replication forks require nuclear DNA2 at sec-
ondary DNA structures, DNA lesions and stalled replica-
tion forks. This suggests that DNA2 may be transported
into the nucleus in response to environmental and endoge-
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nous stimuli (37). The nuclear localization of a vastmajority
of nuclear proteins is mediated by the built-in NLS motif,
which is a cluster of positively charged amino acid residues
that binds to the nuclear transport protein importin  (38).
Proteins that lack an NLS may interact with other proteins
that contain an NLS to enter the nucleus via a piggyback
transport mechanism (39). Several studies have also sug-
gested that the protein ubiquitination system may mediate
nuclear transport in an NLS-independent fashion (39–41).
Here, we report that nuclear hDNA2 is ubiquitinated
and that hDNA2 ubiquitination is significantly increased in
response to DNA-damaging agents such as camptothecin
(CPT) and hydroxurea (HU). We further reveal that human
TRAF6 (hTRAF6), an E3 ligase, binds to hDNA2 and me-
diates its K63 ubiquitination, which promotes its stability
and nuclear localization. Genetic or chemical inhibition of
hTRAF6 or hDNA2 activity abolishes the ubiquitination
and nuclear localization of hDNA2, consequently impair-
ing DNA end resection and homology-directed recombi-
nation repair (HDR) of DSBs. Thus, the current work re-
veals the role of hTRAF6-mediated ubiquitination in regu-
lating the nuclear transport of hDNA2 to maintain nuclear
genome integrity.
MATERIALS AND METHODS
Cell culture
All cells were cultured in Dulbecco’s Modified Ea-
gle’s Medium (DMEM; Gibco) supplemented with
10% fetal bovine serum (FBS; Sigma) and 100 U/ml
Penicillin/Streptomycin (Genesee Scientific). DNA2
knockdown HeLa and 293T cell lines were constructed
using a lentivirus as previously described (42). Briefly,
lentiviruses were produced by co-transfection of 293T cells
with pResQ shDna2′, psPAX2 and pMD2.G (4:3:1 ratio).
Viruses were collected 48 h post-transfection. Infection
was carried out overnight in the presence of 10 g/ml
protamine sulfate. A total of 2 g/ml of puromycin was
added 48 h post-infection to select for infected cells.
Knockdown efficiency was confirmed using western blot
analysis. pResQ shDna2 was a gift from Sheila Stewart
(Addgene plasmid #31952).
RNA interference and drug treatment
HeLa cells were transfected with scrambled siRNA con-
trol oligos or siRNA oligos specifically against TRAF6
(Bioland) using Lipofectamine 2000 transfection reagent
(Thermo Fisher) or transfected with scrambled control
shRNA or shRNA pLV-EGFP:T2A:Puro-U6-hTRAF6
from VectorBuilder (https://en.vectorbuilder.com/). After
48–72 h, the cells were harvested and lysed. Knock-
down efficiency was confirmed using quantitative RT-
PCR. hTRAF6 siRNA targeting sequences: GCAGUGCA
AUGGAAUUUAUTT, CCCAGUCACACAUGAGAA
UTT and GCAAAUGUCAUCUGUGAAUTT. TRAF6
shRNA target sequence: AGCGCTGTGCAAACTATA
TAT.
Cycloheximide (CHX, 50g/ml, purity: 95%) orMG132
(1 M, purity:>90%) was added to the cell media for 0−24
h to inhibit protein synthesis or degradation, respectively.
CPT (1 M; purity: 99%; Sigma) or HU (1 mM; purity:
98%; Sigma) was added to the cell media for 4 or 16 h,
respectively, before cell collection. The TRAF6 E3 ligase
inhibitor C25–140 (ChemDiv, Catalog #G827–0140) was
added for 48 h at a final concentration of 30 M. The
TRAF6 inhibitory peptide T6PD (Novus Biologicals, Cat-
alog #NBP2–26506) was added for 24 h at a final con-
centration of 100 M. The ataxia-telangiectasia mutated
(ATM) inhibitor KU-55933 (Abcam, Catalog #ab120637)
was added for 12 h at a final concentration of 10 M.
Protein expression and purification
Recombinant protein expression in mammalian cells and
protein purification were conducted as previously described
(27). Briefly, 293T cells were transfected with 3xFlag-
hDNA2 or myc-hTRAF6 using the Polyjet (SignaGen)
transfection reagent. Twenty-four hours after transfection,
the cells were collected and lysed by brief sonication in the
immunoprecipitation (IP) buffer H150 (50 mM HEPES-
KOH [pH7.4], 150mMNaCl, 0.1%NP40 and 10%glycerol)
with protein inhibitor cocktail (Thermo Fisher). After cen-
trifugation (20,000 × g, 15 min, 4◦C), the supernatant was
incubated with anti-Flag M2 magnetic beads (Sigma) or
anti-myc magnetic beads (Thermo Fisher) overnight. The
beads were washedwithH500 buffer (50mMHEPES-KOH
[pH7.4], 500 mM NaCl, 0.1% NP40 and 10% glycerol) and
H150 buffer (50mMHEPES-KOH [pH7.4], 150mMNaCl,
0.1% NP40 and 10% glycerol) once, then eluted with 250
g/ml 3xFlag peptide or myc peptide (Apex) for 6 h.
Immunoprecipitation
293T cells were transfected with 3xFlag-hDNA2 or myc-
hTRAF6 alone or in combination using the Polyjet (Signa-
Gen) transfection reagent. Twenty-four hours after trans-
fection, the cells were collected and lysed by brief soni-
cation in the IP buffer H150 with protein inhibitor cock-
tail (Thermo Fisher). After centrifugation (20,000 × g, 15
min, 4◦C), the supernatant was incubated with anti-Flag
M2 magnetic beads (Sigma) or anti-myc magnetic beads
(Thermo Fisher) overnight. The beads were washed three
times with H150 buffer, and then eluted with 250 g/ml
3xFlag peptide or myc peptide (Apex) for 6 h. The 3xFlag-
hDNA2 or myc-hTRAF6 was subjected for analysis by
western blot analysis or mass spectrometry.
To immunoprecipitate endogenous hDNA2, HeLa cell
lysate was incubated with an anti-hDNA2 antibody and
Protein A/G dynabeads in the IP buffer overnight. The
beads were washed three times with H500 buffer and
subjected to boiling in 1× sodium dodecyl sulphate-
polyacrylamide gelelectrophoresis (SDS-PAGE) loading
buffer directly. hDNA2 levels were analyzed by western blot
analysis.
Mass spectrometry
To detect the DNA2 ubiquitination sites, 3xFlag-hDNA2,
myc-hTRAF6 and 6His-tagged ubiquitin were co-
transfected in 293T cells. Total 3xFlag-hDNA2 proteins
were purified using anti-Flag M2 beads. Purified 3xFlag-
hDNA2 proteins were resolved in an 8% SDS-PAGE gel.
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The gel was stained with Coomassie, and the DNA2 bands
were cut and subjected to mass spectrometry (Shanghai In-
stitute of Material Medica, Chinese Academy of Sciences).
Briefly, the excised gel containing 3xFlag-hDNA2 was cut
into pieces and washed with water. It was then destained
and dehydrated with acetonitrile. Dithiothreitol (DTT)
and NH4HCO3 were added to final concentrations of 20
mM and 50 mM, respectively. The mixture was incubated
at 56◦C for 30 min. The gel was destained with acetonitrile
again. Iodoacetamide (IAA) and NH4HCO3 were added to
final concentrations of 100 mM and 50 mM, respectively.
After incubation for 20 min in the dark, in-gel tryptic
digestion was carried out at 37◦C overnight. The digested
sample was dissolved in 0.1% formic acid and cleared by
centrifugation (room temperature, 20,000 × g, 15 min).
The supernatant was analyzed using an Orbitrap Elite
Hybrid Mass Spectrometer (Thermo Fisher). The data was
analyzed using MaxQuant software (43).
Subcellular fractionation
Subcellular fractionation of proteins into cytoplasmic and
nuclear fractionswas performed according to the previously
published protocol with slight modifications (44). Briefly,
harvested HeLa or 293T cells were washed with hypotonic
buffer (20 mM Tris–HCl [pH7.5], 10 mM NaCl, 10% glyc-
erol, 1 mMphenylmethylsulfonyl fluoride (PMSF) and pro-
tein inhibitor cocktail) without detergent. The cells were
then incubated in hypotonic buffer containing 0.1% NP40
on ice for 5 min. The cell lysate was centrifuged at low speed
(1,300 × g, 5 min, 4◦C). The supernatant was transferred
into a new 1.5 ml tube and subjected to another round of
centrifugation (20,000 x g, 15 min, 4◦C). The cleared super-
natant was kept as the cytoplasmic fraction. The nuclear
fraction was extracted using nuclear extraction buffer (20
mM Tris–HCl [pH7.5], 500 mM NaCl, 10% glycerol, 0.1%
NP40, 1 mM PMSF and protein inhibitor cocktail). After
brief sonication, the pellets were centrifuged (20,000× g, 15
min, 4◦C). The supernatant was kept as the nuclear fraction.
Subcellular fractionation of proteins into cytosolic, mi-
tochondrial and nuclear fractions was performed using the
Mitochondrial Isolation Kit for Cultured Cells (Thermo
Scientific) using the protocol provided by the supplier with
modifications. Briefly, 20 million cells expressing 3xFlag-
hDNA2or 3xFlag-hDNA2 andmyc-hTRAF6werewashed
with phosphate buffered saline (PBS) and incubated on ice
in Reagent A for 2 min. Reagent B was added, and the mix-
ture was incubated on ice for 5 min. Reagent C was added,
and the contents were mixed by inverting the tube several
times, followed by centrifugation (700 × g, 10 min, 4◦C).
The supernatant (cytosol plus mitochondria) was collected
and centrifuged (12,000 ×g, 15 min, 4◦C). The supernatant
(cytosol) was centrifuged (20,000 × g, 15 min, 4◦C) to re-
move trace amounts of debris. The pellet (mitochondria)
was washed with Reagent C twice to remove cytosolic con-
tamination. The nuclear pellet was washed twice with wash
buffer (10 mM Tris–HCl [pH 7.5], 10 mM KCl and 0.4%
NP) to remove non-lysed cells and mitochondrial contami-
nants. A total of 1 mM PMSF and protease inhibitor cock-
tail were added to all solutions before use.
In vitro ubiquitination assays
In vitro ubiquitination assays were performed, as previ-
ously described (42), using the Ubiquitin Conjugation Kit
(Boston Biochem) according the manufacturer’s instruc-
tions. Briefly, 100 ng 3xFlag-hDNA2 and the E2 mixture
from the kit were reacted either with the E3 mixture from
the kit or an equivalent amount of purified myc-hTRAF6
at 37◦C in a water bath for 90 min. Reactions were detected
by western blot analysis using an anti-ubiquitin antibody.
Immunofluorescence
Detection of phosphor-RPA (S33) was carried out follow-
ing the previously published protocol (11). Briefly, HeLa
cells were grown on coverslips. After transfection and/or
drug treatment, the cells were fixed with 4% paraformalde-
hyde (PFA) at room temperature for 30 min and permeabi-
lized in 0.15% Triton X-100 for 15 min at room temper-
ature. The coverslips were blocked with 5% bovine serum
albumin for 1 h and then incubated with the primary an-
tibody (specified in the figure legends) at room temper-
ature for 2 h or at 4◦C overnight. After washing with
PBS buffer, the coverslips were incubated with Alexa-555-
conjugated secondary antibodies (1:150, Life Technologies)
at room temperature for 1 h. After washing with PBS, the
coverslips were incubated with DAPI solution (Thermo
Fisher, Catalog #62248) to stain the nuclei. The coverslips
were mounted with ProLong™ Gold Antifade Mountant
(Thermo Fisher, Catalog #P36930) and examined by flu-
orescence microscopy.
DR-GFP-based HDR assay
293T cells carrying the DR-GFP reporter construct were
generated according to a previously published protocol
(45). DNA fragments encoding a pair of single-stranded
guide RNAs (sgRNAs) and Cas9 D10A nickase were sub-
cloned into the multiplex CRISPR/Cas9 vector to simul-
taneously express the sgRNAs and Cas9 D10A (46). The
HDR of CRISPR/Cas9 D10A-induced DSBs in the DR-
GFP reporter construct was carried out as described (45).
Briefly, 3 × 105 cells were seeded. Following pre-treatment
with DMSO, C5 or C25–140, the cells were transfected with
the multiplex gRNA/CAS9D10A vector targeting the DR-
GFP reporter (0.4 g) using Lipofectamine 2000 transfec-
tion mixes. The percentage of GFP+ cells was determined
using fluorescence-activated cell sorting (FACS) analysis 3
days after transfection.
Quantification and statistical analyses
The intensity of immunofluorescence staining was quanti-
fied using ImageJ software (NIH). All data are presented as
the mean± SEM of at least three independent experiments.
P-values for differences between groups were calculated us-
ing two-tailed Student’s t-tests.P< 0.05 was considered sta-
tistically significant.
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RESULTS
Nuclear hDNA2 is ubiquitinated
To test if ubiquitination or other post-translational mod-
ifications of hDNA2 are required for its nuclear localiza-
tion, we isolated cytoplasmic extracts (CE) and nuclear ex-
tracts (NE) fromHeLa cells and analyzed hDNA2 proteins
using western blot analysis. Cytoplasmic hDNA2 had one
major band corresponding to the molecular weight of non-
modified hDNA2 (∼110 kD) and faint bands with molecu-
lar weights >110 kD. In contrast, nuclear hDNA2 showed
distinct bands with molecular weights greater than 120 kD
(Figure 1A). We observed that, in response to treatment
with the DNA-damaging and fork-stalling agent CPT, the
amount of total hDNA2, as well as nuclear hDNA2, in-
creased considerably (Figure 1B). Importantly, levels of nu-
clear hDNA2molecules withmolecular weights higher than
120 kD increased, indicating that covalent attachments of
ubiquitin or SUMO peptides to the hDNA2 protein may
be important for its stability and nuclear translocation. We
then used an anti-hDNA2 antibody to pull down endoge-
nous hDNA2 from the CE and NE. Western blot anal-
ysis of the immunoprecipitated cytoplasmic and nuclear
hDNA2 revealed that nuclear hDNA2 was ubiquitinated
(Figure 1A) but not SUMOylated (data not shown). By
overexpressing 3xFlag-tagged hDNA2 (3xFlag-hDNA2) in
293T cells, we further confirmed that nuclear hDNA2 was
ubiquitinated (Figure 1C).Moreover, upon treatment of the
cells with CPT or HU, hDNA2 ubiquitination increased
substantially (Figure 1C). These findings suggest that, in
response to replication stress induced by environmental
agents, hDNA2 is ubiquitinated and subsequently translo-
cated into the nucleus.
hTRAF6 interacts with hDNA2 and catalyzes its ubiquitina-
tion
We subsequently sought to identify the ubiquitin E3 lig-
ase that ubiquitinates hDNA2 and mediates hDNA2 nu-
clear translocation in response toDNA-damaging and fork-
stalling agents. A previous study revealed that ATM ki-
nase, the master DNA damage-sensing protein (47), mi-
grates to the cytoplasm in response to DNA damage (48).
Cytoplamic ATM then activates the ubiquitin E3 ligase
TRAF6, which catalyzes K63-linked polyubiquitination
(49), to transduce the DNA damage signal to the NF-B
pathway to regulate cell proliferation and survival (48). It
is possible that cytoplasmic ATM-triggered hTRAF6 acti-
vation also mediates the nuclear translocation of DNA re-
pair proteins, such as hDNA2, in response to DNA dam-
age. To determine if hTRAF6 mediates hDNA2 nuclear lo-
calization, we first expressed 3xFlag-hDNA2 in 293T cells
and conducted co-immunoprecipitation assays to deter-
mine if hDNA2 and hTRAF6 interact. We found that en-
dogenous hTRAF6 was pulled down with 3xFlag-hDNA2
(Figure 2A). To further verify that hDNA2 interacts with
hTRAF6, we co-expressed 3xFlag-hDNA2 andmyc-tagged
hTRAF6 (myc-hTRAF6) in 293T cells and conducted co-
immunoprecipitation assays. We found that myc-hTRAF6
was pulled down with 3xFlag-hDNA2 but not 3xFlag-GFP
using anti-Flag M2 beads (Figure 2B). Consistent with
this finding, 3xFlag-hDNA2 was pulled down with myc-
hTRAF6 using anti-myc beads (Figure 2B). Furthermore,
we found that CPT treatment of cells co-expressing 3xFlag-
hDNA2 and myc-hTRAF6 stimulated the binding of myc-
hTRAF6 and 3xFlag-hDNA2 (Figure 2C).
To determine if hTRAF6 ubiquitinates hDNA2, we
reconstituted hDNA2 ubiquitination reactions using the
ubiquitination enzymes E1 and E2 with or without puri-
fied myc-hTRAF6 or a mixture of other ubiquitin E3 lig-
ases. In the absence of a ubiquitin E3 ligase, little hDNA2
was ubiquitinated (Figure 2D). On the other hand, the ad-
dition of purified recombinant hTRAF6 greatly enhanced
the ubiquitination of hDNA2 (Figure 2D). hDNA2 was
also ubiqutinated with the addition of a mixture of E3
ligases (Figure 2D), suggesting that E3 ligases other than
hTRAF6 may also catalyze hDNA2 ubiquitination in vitro.
Co-immunoprecipitation using anti-Flag M2 beads and
western blot analysis indicated that overexpression of myc-
hTRAF6 enhanced the ubiquitination of 3xFlag-hDNA2
(Figure 2E). To further demonstrate that hTRAF6mediates
hDNA2 ubiquitination, we co-expressed 3xFlag-hDNA2,
6His-tagged ubiquitin and wild-type (WT) hTRAF6 or the
E3 ligase activity-deficient hTRAF6 mutant C70A in 293T
cells. We isolated 6His-tagged ubiquitin-linked proteins un-
der denaturing conditions (8 M urea), and western blot
analysis of the 6His-tagged ubiquitin-linked hDNA2 re-
vealed that the expression of hTRAF6 enhanced hDNA2
ubiquitination; however, this effect was dramatically lower
for the C70A hTRAF6 mutant compared to WT hTRAF6
(Figure 2F). It is worth noting that expression of C70A
hTRAF6 did not completely abolish ubiquitination of
hDNA2 (Figure 2F). This suggests that there are other
E3 ligases that mediate different forms of hDNA2 polyu-
biquitination in these cells. In addition, we tested the ef-
fects of K27R, K48R and K63R ubiquitin mutations on
hDNA2 ubiquitination. We found that considerably less
K27R and K63R ubiquitin was linked to hDNA2 thanWT
and K48R ubiquitin in 293T cells expressing exogenous
hTRAF6 (Figure 2G). This finding is consistent with find-
ings that TRAF6 mediates K27-linked (50) and K63-linked
ubiquitination (49).
hTRAF6-mediated ubiquitination enhances hDNA2 stability
and nuclear localization
We sought to determine if hTRAF6 plays a role in mod-
ulating hDNA2 protein levels and nuclear translocation.
We first evaluated hDNA2 protein and mRNA levels in
cells with hTRAF6 overexpressed or knocked down. West-
ern blot analysis revealed that overexpression of ubiqui-
tin and myc-hTRAF6 greatly enhanced 3xFlag-hDNA2
ubiquitination, as well as total 3xFlag-hDNA2, in 293T
cells (Figure 3A). To further assess the impact of hTRAF6
on hDNA2 stability, we treated cells expressing 3x-Flag-
hDNA2 or 3xFlag-hDNA2 and myc-hTRAF6 with cyclo-
heximide (CHX) to block protein synthesis or with MG132
to block proteasome-mediated protein degradation. We ob-
served that 3xFlag-hDNA2 levels were gradually reduced
with prolonged CHX treatment in cells without hTRAF6,
but expression of hTRAF6 prevented such reduction (Fig-
ure 3B). Meanwhile, 3xFlag-hDNA2 gradually accumu-
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Figure 1. Nuclear hDNA2 is ubiquitinated. (A) Immunoprecipitation and western blot analysis of hDNA in cytosplasmic extract (CE) andNE and soluble
chromatin (chr) fractions of HeLa cells using anti-hDNA2 or anti-ubiquitin (Ubn) antibodies. GAPDH and histone H3 were used as CE and NE+Chr
markers, respectively. (B) HeLa cells were treated with DMSO (control) or CPT (1 M). After 4 h, hDNA2 in the CE and NEwas analyzed by western blot
analysis using an anti-hDNA2 antibody. GAPDH and histone H3 were used as CE and NE markers, respectively. (C) 293T cells overexpressing 3xFlag-
hDNA2 were treated with UV (250 J/m2), H2O2 (1 mM, 15 min), CPT (1 M, 4 h) or HU (1 mM, 16 h). 3xFlag-hDNA2 was purified using anti-Flag M2
beads and its ubiquitination status was evaluated by western blot analysis using an anti-ubiquitin antibody.
lated upon MG132 treatment in cells without hTRAF6
and was at consistently high levels, even without MG132
treatment, in cells with hTRAF6 (Figure 3C), suggesting
that expression of hTRAF6 blocks proteasome-mediated
hDNA2 degradation. To determine if TRAF6-mediated
hDNA2 ubiquitination is important for hDNA2 stabiliza-
tion, we co-expressed 3xFlag-hDNA2 with WT or C70A
hTRAF6 and with or without HA-tagged ubiquitin. We
observed that WT hTRAF6 induced hDNA2 ubiquitina-
tion and stability, but the catalysis-defective C70A mu-
tant only partially enhanced hDNA2 stabilization (Figure
3D). These results suggest that hTRAF6-mediated ubiqui-
tination of hDNA2 increases its stability, likely by block-
ing the proteasome-mediated degradation of hDNA2. In
addition, the physical interaction between hTRAF6 and
hDNA2 may also contribute to preventing hDNA2 degra-
dation. Consistent with these findings, overexpression of
ubiquitin andmyc-hTRAF6 increased endogenous hDNA2
expression in HeLa cells (Figure 3E). Conversely, knock-
down of hTRAF6 diminished endogenous hDNA2 inHeLa
cells (Figure 3F). However, the overexpression and knock-
down of hTRAF6 did not change hDNA2 mRNA levels
(Figure 3E and F). These findings suggest that hDNA2
ubiquitination by hTRAF6 enhances its stability in a post-
translational manner.
We then determined if hDNA2 nuclear localization
was dependent on hTRAF6-mediated ubiquitination of
hDNA2. We conducted western blot analysis of hDNA2
in the CE and NE from cells with or without hTRAF6
overexpression. We found that overexpression of hTRAF6
promoted nuclear localization of endogenous hDNA2 (Fig-
ure 4A). To further investigate the impact of hTRAF6 on
hDNA2 ubiquitination and nuclear localization, we over-
expressed 3xFlag-hDNA2 with or without co-expression of
myc-hTRAF6. Western blot analysis revealed that overex-
pression of WT, but not C70A mutant hTRAF6, greatly
induced ubiquitination of 3xFlag-hDNA2 in both CE and
NE and enhanced nuclear localization of 3xFlag-hDNA2
(Figure 4B). Furthermore, in the presence of C25–140, a
small molecule that specifically inhibits hTRAF6 ubiqui-
tin E3 ligase activity (51), hDNA2 ubiquitination and nu-
clear localization were greatly inhibited (Figure 4C). In
contrast, a cell-permeable TRAF6 decoy peptide (T6DP),
which specifically disrupts the TRAF6/RANK interaction
(52), had little impact on TRAF6-induced hDNA2 ubiq-
uitination and nuclear localization (Figure 4D). We also
noticed that in the presence of C25–140, TRAF6 could at
least partially stabilize hDNA2 (Figure 4C). This observa-
tion is consistent with our suggestion that the physical inter-
action between TRAF6 and hDNA2 contributes to the pre-
vention of hDNA2 degradation. In addition, we found that
the ATM inhibitor KU55933 (53) also inhibited hTRAF6-
mediated hDNA2 nuclear localization (Figure 4E). This is
consistent with previous findings that hTRAF6 activation
in response to DNA damage is mediated by ATM (48). To
determine if treatment with CPT induces hDNA2 nuclear
localization in anATM-dependentmanner, we treated 293T
cells expressing 3xFlag-hDNA2 with CPT in the presence
or absence of KU55933. We found that KU55933 blocked
CPT-induced hDNA2 nuclear localization (Figure 4F).
Ubiquitination at the N-terminus of hDNA2 is critical for its
stability and nuclear localization
We used mass spectrometry to identify the hTRAF6-
mediated ubiquitination sites in ubiquitinated hDNA2 iso-
lated from 293T cells co-expressing 3xFlag-hDNA2, myc-
hTRAF6 and ubiquitin. A total of 20 lysine residues were
identified (Figure 5A and Supplementary Figure S1). To
determine which sites are important for the nuclear lo-
calization of hDNA2, we expressed and purified the N-
terminal nuclease domain (amino acids 1–382) and C-
terminal ATPase and helicase domain (amino acids 383–
1060) of 3xFlag-hDNA2. We overexpressed full-length,
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Figure 2. hTRAF6 interacts with hDNA2 and catalyzes its ubiquitination. (A) 293T cells were transfected with a 3xFlag-hDNA2 or an empty control
vector (EV). The 3xFlag-hDNA2 complex was pulled down using anti-Flag M2 beads. The endogenous hTRAF6 in complex with 3xFlag-hDNA2 was
detected using anti-hTRAF6 antibody. (B) 3xFlag-hDNA2 and myc-hTRAF6 were co-expressed in 293T cells. In control reactions, myc-hTRAF6 was co-
expressed with 3xFlag-GFP and 3xFlag-hDNA2 was co-expressed with a non-specific peptide encoded by the empty myc vector. 3xFlag-hDNA2 and the
myc-hTRAF6 complex were pulled down using anti-Flag M2 or anti-myc affinity beads. myc-hTRAF6 and 3xFlag-hDNA2 were detected by western blot
analysis using anti-myc or anti-Flag antibodies. (C) 293T cells co-expressing 3xFlag-hDNA2 and myc-hTRAF6 were treated with DMSO or CPT (1 M,
4 h). 3xFlag-hDNA2 and myc-hTRAF6 were pulled down and analyzed by western blot, as described for panel (B). (D) In vitro reconstitution of hDNA2
ubiquitination using ubiquitin (Ubn) and purified recombinant myc-hTRAF6, 3xFlag-hDNA2, ubiquitination enzymes E1 and E2, and mixed E3 ligases.
(E) 3xFlag-hDNA2 was co-expressed with 6His-tagged Ubn (6His-Ubn) and myc-hTRAF6 in 293T cells. Total hDNA2 was isolated using anti-Flag M2
beads and the ubiquitination status of 3xFlag-hDNA2 was analyzed by western blot analysis using an anti-6His antibody. (F) 3xFlag-hDNA2 was co-
expressed with 6His-Ubn and WT myc-hTRAF6 or C70A (ubiquitin E3 ligase activity-deficient) mutant myc-hTRAF6 in 293T cells. Total ubiquitinated
proteins were isolated using Ni-NTA beads under denaturing conditions (8 M urea). 6His-Ubn-linked hDNA2 was detected by western blot analysis using
an anti-Flag antibody. (G) 3xFlag-hDNA2 was co-expressed with HA-taggedWT, K27R, K48R or K63R ubiquitin (HA-Ubn) and myc-hTRAF6 in 293T
cells. Total hDNA2 was isolated using anti-Flag M2 beads, and the ubiquitination status of 3xFlag-hDNA2 was analyzed by western blot analysis using
an anti-HA antibody.
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Figure 3. hTRAF6-mediated hDNA2 ubiquitation is important for the stability of hDNA2. (A) 3xFlag-hDNA2 was expressed alone or with 6His-Ubn
and/or myc-hTRAF6 in 293T cells. 3xFlag-hDNA2 was detected by western blot analysis using an anti-Flag antibody. GAPDH was used as an internal
control. The ubiquitination status of 3xFlag-hDNA2 was analyzed as described for Figure 2D. (B and C) 293T cells were transfected with 3xFlag-hDNA2
and an empty control vector (EV) or myc-hTRAF6. The cells were treated with CHX (panel B, 50 g/ml) or MG132 (Panel C, 1 M) and harvested and
lysed at 0, 2, 4, 8, 12 or 24 h. 3xFlag-hDNA2 levels were determined by western blot using anti-Flag antibody. GAPDH was used as a loading control.
(D) 3xFlag-hDNA2 was co-expressed with WT or C70A mutant myc-hTRAF6 and with empty vector (EV) or the vector expressing HA-ubiquitin (HA-
Ubn). In the controls, 3xFlag-hDNA2 expression vector was co-transfected with EV or HA-Ubn vector. 3xFlag-hDNA2 levels were determined by western
blot using anti-Flag antibody. (E) 6His-Ubn and/or myc-hTRAF6 were overexpressed in HeLa cells, and endogenous hDNA2 protein and mRNA levels
were evaluated by western blot analysis and RT-PCR, respectively. HeLa cells harboring EV only were used as the control. GAPDH was used as an
internal control for comparison of hDNA2 levels in different cells. (F) HeLa cells were transfected with a scrambled negative control siRNA (siNC) or
siRNA against hTRAF6 (sihTRAF6). Endogenous hDNA2 protein and mRNA levels were evaluated by western blot analysis and RT-PCR, respectively.
hTRAF6 knockdown efficacy was confirmed by RT-PCR. GAPDH was used as an internal control.
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Figure 4. hTRAF6 promotes hDNA2 nuclear localization. (A) HeLa cells were transfected with an empty control vector (EV) or a vector encoding myc-
hTRAF6. Endogenous hDNA2 protein in the CE and NE was analyzed by western blot analysis using an anti-hDNA2 antibody. GAPDH and histone
H3 were used as CE and NE markers, respectively. (B) 3xFlag-hDNA2 was co-expressed with EV or a vector encoding WT or C70A (ubiquitin E3 ligase
activity-deficient) mutant hTRAF6 in 293T cells. 3xFlag-hDNA2 in the CE and NE was analyzed by western blot analysis using an anti-Flag antibody.
GAPDH and histone H3 were used as CE and NE markers, respectively. (C–E) 293T cells co-expressing 3xFlag-hDNA2 and myc-hTRAF6 were left
untreated or were treated with (C) a small molecule inhibitor of TRAF6 E3 ligase activity (C25–140, 30 M, 48 h), (D) a TRAF6/RANK interaction-
disrupting peptide (T6DP, 100 M, 24 h) or (E) a small molecule ATM kinase activity inhibitor (KU-55933, 10 M, 16 h). 3xFlag-hDNA2 levels in the
CE and NE were analyzed by western blot analysis using an anti-Flag antibody. GAPDH and histone H3 were used as CE and NE markers, respectively.
(F) 293T cells expressing 3xFlag-hDNA2 were pre-treated with DMSO (control) or KU-55933 (10 M, 16 h). The cells were left untreated or were treated
with CPT (1 M, 4 h). 3xFlag-hDNA2 levels in the CE and NE were analyzed by western blot analysis using an anti-Flag antibody. GAPDH and histone
H3 were used as CE and NE markers, respectively.
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Figure 5. Ubiquitination at the N-terminal nuclease domain of hDNA2 is critical for its stability and nuclear localization (See also Supplementary Figures
S1 and 2). (A) The domain structure and ubiquitinated lysine residues of hDNA2 that were identified by mass spectrometry. (B) 3xFlag-hDNA2 protein
(full-length [1–1060], N-terminal [1–382], or C-terminal [383–1060]) was overexpressed alone or with myc-hTRAF6 in 293T cells. 3xFlag-hDNA2 protein
levels in the CE and NE were analyzed by western blot analysis using an anti-Flag antibody. GAPDH and histone H3 were used as markers for the
cytoplasmic and nuclear fractions, respectively. (C) Immunoprecipitation and western blot analysis of hTRAF6-mediated ubiquitination of WT or 6KR
mutant hDNA2, conducted as described for Figure 2D. (D) The subcellular localization of 3xFlag WT and 6KR mutant hDNA2 in the cytoplasmic (C)
and nuclear (N) fractions was analyzed as described for panel (B).
N-terminal and C-terminal 3xFlag-hDNA2 in 293T cells
alone or withmyc-hTRAF6.Without hTRAF6 overexpres-
sion, C-terminal hDNA2 was undetectable, compared to
full-length and N-terminal hDNA2, in CE (Figure 5B).
With hTRAF6 overexpression, C-terminal hDNA2 was de-
tected, albeit at much lower levels than full-length and
N-terminal hDNA2. This observation is consistent with
our finding that hTRAF6 promotes hDNA2 stability and
suggests that hTRAF6-mediated stability of hDNA2 oc-
curs predominantly through its N-terminal ubiquitina-
tion, although C-terminal ubiquitination can also stabilize
hDNA2 in the absence of the N-terminal if TRAF6 is over-
expressed. Furthermore, overexpression of hTRAF6 stimu-
lated the nuclear localization ofN-terminal hDNA2 but not
C-terminal hDNA2 (Figure 5B), suggesting that the ubiqui-
tination sites in the N-terminus of hDNA2 play a predom-
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Figure 6. hTRAF6-mediated ubiquitination of hDNA2 enhances its nuclear and mitochondrial localization. (A and B) Subcellular localization of (A)WT
and (B) 6KR 3xFlag-hDNA2 in fractionated 293T cells. Tubulin, Cox IV and histone H3 were used as markers of the cytosolic, mitochondrial and nuclear
fractions, respectively. (C and D) Subcellular localization of (C) WT and (D) 6KR 3xFlag-hDNA2 in the presence or absence of myc-hTRAF6 expression
in fractionated 293T cells. Tubulin, Cox IV and histone H3 were used as markers of the cytosolic, mitochondrial and nuclear fractions, respectively.
inant role in hTRAF6-mediated hDNA2 nuclear translo-
cation. We therefore constructed a mutant by simultane-
ous substituting the N-terminal ubiquitination site lysine
residues (K29, K194, K275, K303, K377 and K434) with
arginine residues (6KR). The 6KR mutant hDNA2 had re-
markably reduced ubiquitination compared toWT hDNA2
(Figure 5C) and nearly failed to translocate into the nucleus
(Figure 5D). Individual substitution of K29, K194, K275,
K303 and K434 with the arginine residue resulted in only
partial defects in hTRAF6-mediated nuclear localization of
hDNA2 (Supplementary Figure S2).
Next, we investigated if TRAF6-mediated hDNA2
ubiquitination affected its mitochondrial localization. We
confirmed that 3xFlag-hDNA2, similar to endogenous
hDNA2, localized to mitochondria and nuclei (Figure 6A).
On the other hand, although the 6KR mutant hDNA2
also localized into mitochondria, only a little 6KR mu-
tant protein localized to the nuclei (Figure 6B). When we
co-expressed WT and 6KR hDNA2 with myc-hTRAF6 in
293T cells, we found that expression of myc-hTRAF6 en-
hanced both the mitochondrial and nuclear localization of
WT hDNA2 (Figure 6C). In contrast, although expression
of myc-hTRAF6 considerably increased the mitochondrial
localization of 6KR, it did not affect the nuclear localization
of 6KR (Figure 6D). These findings indicate that hTRAF6-
mediated ubiquitination regulates the mitochondrial and
nuclear localization of hDNA2, and ubiquitination at its N-
terminus is specifically crucial for its nuclear localization.
hTRAF6-mediated hDNA2 ubiquitination facilitates DNA
end resection and HDR
A major function of hDNA2 in counteracting replication
stress is resecting DNA ends at DSBs to generate 3′ single-
stranded DNA (ssDNA) overhangs for homologous re-
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Figure 7. The hDNA2 6KR mutation impairs CPT-induced ssDNA production. Staining for pRPA was conducted using an anti-pRPA (S33) antibody
to detect CPT-induced ssDNA regions, which is a readout of CPT-induced fork processing. (A) Representative immunofluorescence images for pPRA in
HeLa cells transfected with scrambled control shRNA (shControl) or shRNA against hDNA2 (shDNA2), plus plasmids expressing WT or 6KR hDNA2,
upon treatment with DMSO or CPT (1 M, 4 h). Green: 3xFlag-hDNA2; red: pRPA (s33); blue: DAPI-stained nuclei. (B) Quantification of pRPA in
HeLa cells under various conditions, as described for panel (A). pRPA intensity was quantified using ImageJ software. The relative intensity of pRPA in
the cells treated with shControl was arbitrarily set to 1. All data are expressed as mean± SEMof at least three independent assays.P-values were calculated
using two-tailed Student’s t-tests. (C) Immunoprecipitation and western blot analysis of pRPA (s33) in HeLa cells under various conditions, as indicated
in the panel.
combination during the repair of replication-related DSBs
(13). To test if the 6KR hDNA2 mutation, which abol-
ishes hTRAF6-mediated hDNA2 ubiquitination and nu-
clear localization, causes defects in ssDNA production dur-
ing HDR, we expressed WT or 6KR in HeLa cells with
hDNA2 stably knocked down (knockdown efficiency was
confirmed by quantitative RT-PCR, Supplementary Fig-
ure S3A). We treated the HeLa cells with CPT (1 M)
to induced replication-associated DSBs (54). We used im-
munofluorescence and western blot analysis to evaluate the
level of RPA phosphorylation (pRPA; S33), which is a com-
mon readout for ssDNAs arising during DNA repair (11).
We observed that CPT induced a significant increase in
pRPA levels in the cells (Figure 7). However, upon CPT
treatment, pRPA levels were significantly lower in hDNA2
knockdown HeLa cells than in WT HeLa cells (Figure 7).
Furthermore, CPT-induced pRPA levels were partially re-
stored in hDNA2 knockdown HeLa cells upon expression
of WT but not 6KR hDNA2 (Figure 7).
Given that hTRAF6-mediated hDNA2 ubiquitination
promotes hDNA2 stability and nuclear localization, inhibi-
tion of this process is expected to cause defects in DNA end
resection and HDR similar to those observed in 6KR mu-
tant HeLa cells. To test this hypothesis, we knocked down
hTRAF6 in HeLa cells (Supplementary Figure S3B). We
measured pRPA levels using immunofluorescence staining
in HeLa cells with or without hTRAF6 knockdown and
treated with CPT. In the absence of CPT, pRPA levels were
low and not significantly impacted by hTRAF6 knockdown
(Figure 8A and B). CPT treatment induced an increase
in pRPA levels, but this effect was inhibited by hTRAF6
knockdown (Figure 8AandB). Consistentwith this finding,
treatment with the TRAF6 E3 ligase activity inhibitor C25–
140 similarly inhibited CPT-induced pRPA (Figure 8C and
Supplementary Figure S4A). In contrast, treatment with
the TRAF6/RANK interaction-inhibiting peptide T6DP
had little effect on CPT-induced pRPA (Figure 8D and
Supplementary Figure S4B). Next, we used a modified ver-
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/advance-article-abstract/doi/10.1093/nar/gkz537/5520579 by C
alifornia Institute of Technology user on 24 June 2019
12 Nucleic Acids Research, 2019
Figure 8. Inhibition of hTRAF6-mediated hDNA2 ubiquitination impairs DNA end resection and HDR (See also Supplementary Figures S3–5). (A–D)
Immunofluorescence staining for pRPA (red) was conducted using an anti-pRPA (S33) antibody. Nuclei were stained with DAPI (blue). (A) Representative
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sion of the CRISPR/Cas9-based direct repeat GFP (DR-
GFP) reporter HDR assay (45) to test if hTRAF6 inhi-
bition impairs overall HDR efficiency. In a modified ver-
sion of the DR-GFP reporter assay (Supplementary Fig-
ure S5), we used the double-nicking CRISPR/Cas9 D10A
system (55) rather than the WT CRISPR/Cas9 system, to
specifically introduce DSBs at the indicated site to initi-
ate HDR (Supplementary Figure S5). The CRISPR/Cas9
D10A-basedDR-GFP construct was inserted into the 293T
genome. Without the DR-GFP construct or the expres-
sion of sgRNA/Cas9 D10A nickase, using the multiplex
CRISPR/Cas9 vector (46),<1% of GFP-positive cells were
observed (Figure 8E, F and J). However, significantly more
293T cells were GFP-positive (Figure 8G and J,P< 0.0001)
in the presence ofDR-GFPand sgRNA/Cas9D10A,which
induced DSBs and subsequent HDR. However, the double-
nicking-induced HDR of DR-GFP was significantly inhib-
ited in cells pretreated with the DNA2 inhibitor C5 or the
TRAF6 inhibitor C25–140 (Figure 8H–J; P < 0.0001 for
both cases). These findings indicate that hTRAF6 inhibi-
tion suppresses HDR, which is consistent with our obser-
vations that hTRAF6 mediates hDNA2 nuclear transloca-
tion.
DISCUSSION
Biochemical and cellular analyses of the DNA2 molecule
and studies of DNA2 knockout mice have provided con-
vincing evidence for the essential roles of hDNA2 and other
mammalian DNA2 proteins in efficient nuclear DNA repli-
cation and repair (11,13,27,31,37,56–58). However, the nu-
clease and helicase activities of DNA2 must be tightly con-
trolled to avoid unwanted processing of DNA structures.
This control may be achieved, at least in part, through a
spatial regulation mechanism. Studies from our group and
others have revealed that levels of nuclear hDNA2 are low
under normal physiological conditions (36,37). In response
to endogenous or environmental genotoxic stresses, how-
ever, hDNA2 migrates into the nucleus and subsequently
binds to chromatin. What mediates the nuclear localiza-
tion of human and other mammalian DNA2 molecules
in the absence of an NLS remains unknown. The current
study reveals that hTRAF6 catalyzes the K27- and K63-
linked polyubiquitination of hDNA2 at its nuclease do-
main, which induces its nuclear localization. Polyubiquiti-
nation of hDNA2 may promote its binding to ubiquitin-
binding domain-containing proteins that have an NLS.
Thus, hDNA2 may be localized to the nucleus via co-
transport with such proteins. Intriguingly, a recent study
suggested that the K63-linked ubiquitin chain also has di-
rect DNA-binding activity (59). Meanwhile, others have
demonstrated that increased DNA-binding affinity is suf-
ficient to drive NLS-independent nuclear localization of
the nuclear protein MeCP2 (60). Therefore, it is also pos-
sible that the K63-linked ubiquitination of hDNA2 pro-
motes its nuclear translocation by increasing its DNA-
binding activity. In addition, a previous study showed that
the monoubiquitination of the tumor suppressor pTEN en-
hances its stability and NLS-independent nuclear accumu-
lation (41). The K63-linked ubiquitination of hDNA2 may
similarly enhances its stability to passively increase its nu-
clear accumulation. On the other hand, we also notice that
majority of 3xFlag-DNA2 in the nucleus with the molec-
ular weight corresponding to the unmodified form. One
possible explanation for this puzzling phenomenon is that
hDNA2 polyubiquitination is a very dynamic process that
is controlled by both the hTRAF6 E3 ligase and deubiq-
uitinases. hTRAF6 catalyzes hDNA2 ubiquitination and
drives its nuclear localization, and once in the nucleus,
hDNA2 may be de-ubiquitinated. Consistent with this hy-
pothesis, our unpublished studies indeed have revealed that
hDNA2 interacts with the deubiquitinases USP24, USP39
and USP44.
The 6KR hDNA2 mutation, which abolishes hDNA2
ubiquitination, causes defects in DNA end resection and
HDR similar to those observed in hDNA2 knockdown
cells. hDNA2 has been shown to be important for DNA
replication in difficult-to-replicate regions, such as cen-
tromeres and telomeres, and to play a role in restarting
stalled replication forks (12,27,31,57). Because all of these
pathways require the presence of hDNA2 in the nucleus, it is
expected that the 6KR hDNA2 mutation will also result in
centromere and telomere defects, contributing to late S/G2
cell-cycle arrest and genomic instability.
The current study also elucidates a new mechanism link-
ingNF-B signaling and theDNAdamage response and re-
pair pathways. TheE3 ubiquitin ligase TRAF6 is a key com-
ponent in the activation of NF-B signaling by cytokines
(61). IL1 and IL1 bind to their receptors to recruit the
adaptor proteins MyD88, IRAK4 and IRAK1, leading to
TRAF6 activation. Activated TRAF6 catalyzes the synthe-
sis of unanchored K63-linked polyubiquitin chains, which
bind to TAB2/TAK1 (61). The activated TAB2/TAK1
complex phosphorylates the IKK kinase complex to acti-
vate NF-B (61). More recently, TRAF6 has been found
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
images of HeLa cells transfected with control shRNA (shControl) or shRNA against hTRAF6 (shTRAF6), followed by CPT treatment (1 M, 4 h). (B)
Relative pRPA levels in the control and TRAF6 knockdown cells treated with DMSO or CPT. (C) Relative pRPA levels in HeLa cells pretreated with
DMSO or C25–140 (30 M, 48 h) followed by treatment with DMSO or CPT (1 M, 4 h). Representative images are shown in Supplementary Figure
S4A. (D) Relative pRPA levels in HeLa cells that were pre-treated with a cell-permeable control peptide (CP) or T6PD peptide (100 M, 24 h), followed by
treatment with DMSO or CPT (1 M, 4 h). Representative images are shown in Supplementary Figure S4B. pRPA intensity was quantified using ImageJ
software. The relative pRPA intensity in the control cells (B: shControl/DMSO; C: DMSO/DMSO; D: CP/DMSO) was arbitrarily set to 1. All data
are expressed as mean ± SEM of at least three independent assays. The P-values were calculated using two-tailed Student’s t-tests. (E–J) CRISPR/Cas9
D10A-basedDR-GFPHDR assay. 293T cells harboring the cassette for the DR-GFP reporter HDR assay were pretreated with DMSO (48 h), C5 (50M,
24 h) or C25–140 (30 M, 48 h). The plasmid encoding CRISPR/Cas9 D10A nickase and a pair of sgRNAs was transfected into the 293T cells to induce
DSB via double-nicking. HDR efficiency was analyzed using flow cytometry. (E–I) Representative flow cytometry plots for parental 293T cells or 293T
DR-GFP cells under various conditions, as indicated in each panel. Counts within the yellow frame were scored as GFP-positive cells. (J) Percentages of
GFP-positive cells among 293TDR-GFP cells under the conditions shown in panels (G–I). Data are expressed asmean± SEMof at least three independent
assays. The P-values were calculated using two-tailed Student’s t-tests.
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to mediate the activation of NF-B by DNA damage in
an ATM-dependent manner (48). DNA damage, especially
DSBs, due to genotoxic stresses is recognized by PARP1,
which recruits and activates ATM (62). The activated ATM
migrates to the cytoplasm and phosphorylates hTRAF6,
which mediates K63 polyubiquitination to activate TAK1
and IKKs (48). Our current study extends this network,
showing that hTRAF6 also catalyzes the polyubiquitina-
tion of hDNA2 to enhance hDNA2 stability and nuclear
localization for DNA repair. These findings suggest that a
key component in the NF-B signaling pathway (TRAF6)
is also used to transduce DNA damage response signals to
regulate the nucleocytoplasmic trafficking of DNA repair
proteins.
The importance of hTRAF6 in DNA repair is under-
scored by evidence that genetic or chemical inhibition of
hTRFA6 impairs the function of hDNA2 in DNA end re-
section and consequently HDR, which is a major pathway
for DSB repair and the rescue of stalled replication forks
(63,64). Because TRAF6-mediated hDNA2 ubiquitination
and nuclear localization occurs not only in response to
stresses but under normal growth conditions, it is likely that
these molecular mechanisms are also important in mediat-
ing other functions of hDNA2 in the nucleus, including cen-
tromere and telomere replication. These findings have im-
portant implications for the role of hTRAF6 in cancer ini-
tiation and progression. Indeed, hTRAF6 is overexpressed
in human cancers and is association with cancer progres-
sion and poor prognosis (65–67). The role of hTRAF6 in
promoting cancer is consistent with its role in the acti-
vation NF-B, which induces the expression of many cell
proliferation and survival genes (68). Furthermore, cancer
cell survival and proliferation rely on the upregulation of
DNA repair pathways to maintain the integrity of the nu-
clear genome in the face of stress due to aberrant DNA
replication, which occurs at high levels in cancer cells (3,4).
hDNA2, which we now show requires hTRAF6, is upregu-
lated in response to replication stress and crucial for DNA
repair processes (11,13,69). Thus, our current study sug-
gests a new role for hTRAF6 in promoting cancer pro-
gression (3,4). Indeed, the inhibition of hTRAF6 not only
blocks NF-B-mediated cell survival signaling but also re-
duces the capacity of cancers cells to counteract DNA repli-
cation stress. Therefore, hTRAF6 may serve as an excellent
target for cancer prevention and treatment. However, the
genetic or chemical inhibition of hTRAF6 can impair the
ability of DNA2 to maintain nuclear genome integrity un-
der normal physiological conditions, which may contribute
to cancer initiation. Therefore, it is important to be mindful
that hTRAF6, likeDNA repair genes, may have both tumor
promoting and suppressive functions.
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